NCT01861496View on ClinicalTrials.gov

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Phase 1: Advanced or Refractory Solid TumoursPhase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer
Interventions
DRUG

LiPlaCis

LiPlaCis IV every 3 weeks on day 1, day 8

Trial Locations (4)

2730

Herlev & Gentofte Hospital, Herlev

3400

Nordsjællands Hospital Hillerød, Hillerød

7100

Vejle Sygehus, Vejle

DK-2100

The Phase One Unit, The Finsen Centre, Rigshospitalet, Copenhagen

Sponsors
All Listed Sponsors
lead

Allarity Therapeutics

INDUSTRY

NCT01861496 - Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours | Biotech Hunter | Biotech Hunter